Chongchuan district in Nantong has been prioritizing the life and health industry as one of its strategic emerging sectors in recent years, with two innovative medical devices approved by the National Medical Products Administration (NMPA).

Jiangsu Bioda Life Science Co's Vasoline Craft, which became the first product of its kind to obtain a domestic innovation certification in December 2024, achieved another milestone in March 2025 by completing clinical implantation cases, marking a breakthrough in domestic vascular access solutions.

Jiangsu Nowyon Medical Devices Co in Chongchuan has also made significant progress. Its newly approved "blood flow-guided dense mesh stent" is the first fully retrievable device that can be removed after microcatheter withdrawal, significantly enhancing surgical safety and effectiveness.

Moving forward, Chongchuan will refine comprehensive support systems for the life and health sector, deepen industry-university-research collaboration, and expedite the commercialization of medical innovations, striving to build a future-oriented industrial hub in the city's core area.

A rendering of life and health industry buildings in Chongchuan district, Nantong. [Photo/WeChat account: chongchuanonline]